CO6811866A2 - Derivados de benzamida sustituida - Google Patents

Derivados de benzamida sustituida

Info

Publication number
CO6811866A2
CO6811866A2 CO13281375A CO13281375A CO6811866A2 CO 6811866 A2 CO6811866 A2 CO 6811866A2 CO 13281375 A CO13281375 A CO 13281375A CO 13281375 A CO13281375 A CO 13281375A CO 6811866 A2 CO6811866 A2 CO 6811866A2
Authority
CO
Colombia
Prior art keywords
benzamide derivatives
substituted benzamide
substituted
derivatives
benzamide
Prior art date
Application number
CO13281375A
Other languages
English (en)
Inventor
Guido Galley
Roger Norcross
Philippe Pflieger
Rene Trussardi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO6811866A2 publication Critical patent/CO6811866A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
CO13281375A 2011-06-10 2013-11-29 Derivados de benzamida sustituida CO6811866A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11169441 2011-06-10

Publications (1)

Publication Number Publication Date
CO6811866A2 true CO6811866A2 (es) 2013-12-16

Family

ID=46298391

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13281375A CO6811866A2 (es) 2011-06-10 2013-11-29 Derivados de benzamida sustituida

Country Status (32)

Country Link
US (1) US9029370B2 (es)
EP (1) EP2718271B1 (es)
JP (1) JP5788087B2 (es)
KR (1) KR101574906B1 (es)
CN (1) CN103596937B (es)
AR (1) AR086880A1 (es)
AU (1) AU2012266462B2 (es)
BR (1) BR112013030698B1 (es)
CA (1) CA2834675C (es)
CL (1) CL2013003485A1 (es)
CO (1) CO6811866A2 (es)
CY (1) CY1116769T1 (es)
DK (1) DK2718271T3 (es)
EA (1) EA022376B1 (es)
EC (1) ECSP13013073A (es)
ES (1) ES2546529T3 (es)
HK (1) HK1192562A1 (es)
HR (1) HRP20151201T1 (es)
IL (1) IL229335A (es)
MA (1) MA35194B1 (es)
MX (1) MX354410B (es)
MY (1) MY162461A (es)
PE (1) PE20140968A1 (es)
PL (1) PL2718271T3 (es)
PT (1) PT2718271E (es)
RS (1) RS54415B1 (es)
SG (1) SG194840A1 (es)
SI (1) SI2718271T1 (es)
TW (1) TWI445701B (es)
UA (1) UA110388C2 (es)
WO (1) WO2012168265A1 (es)
ZA (1) ZA201308401B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
EP2802578B1 (en) 2012-01-12 2015-10-07 F.Hoffmann-La Roche Ag Heterocyclic derivatives as trace amine associated receptors (taars)
MX363362B (es) * 2012-09-14 2019-03-21 Hoffmann La Roche Derivados de pirazol carboxamida como moduladores de los receptores asociados con las aminas traza (taar) para uso en el tratamiento de varios trastornos, tales como depresión, diabetes y enfermedades de parkinson.
ES2605632T3 (es) 2012-09-17 2017-03-15 F. Hoffmann-La Roche Ag Derivados triazol carboxamida
US20160272626A1 (en) * 2012-11-07 2016-09-22 Hoffmann-La Roche Inc. Pyrazine derivatives
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
CN106459073B (zh) * 2014-05-28 2018-11-13 豪夫迈·罗氏有限公司 作为taar1调节剂的5-氧杂-2-氮杂二环[2.2.2]辛-4-基和5-氧杂-2-氮杂二环[2.2.1]庚-4-基衍生物
CN104478798B (zh) * 2014-12-18 2017-01-18 武汉华纳联合药业有限公司 N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用
SI3430010T1 (sl) * 2016-03-17 2020-10-30 F. Hoffmann-La Roche Ag Derivat 5-etil-4-metil-pirazol-3-karboksamida z aktivnostjo agonista TAAR
CA3169099A1 (en) * 2020-02-28 2021-09-02 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
ES2216339T3 (es) 1997-12-04 2004-10-16 Allergan, Inc. Derivados sustituidos de imidazol que tienen actividad de tipo agonista hacia los receptores adrenergicos alfa 2b o 2b/2c.
TW200621760A (en) * 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
CA2675471A1 (en) 2007-02-02 2008-08-07 Novartis Ag Chromene s1p1 receptor antagonist
BRPI0807813A2 (pt) 2007-02-15 2014-08-05 Hoffmann La Roche 2-amino-oxazolinas como ligantes de taar1
WO2009016088A1 (en) 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag The use of benzamide derivatives for the treatment of cns disorders
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
JP5699149B2 (ja) 2009-09-04 2015-04-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド Bruton型チロシンキナーゼ阻害薬
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives

Also Published As

Publication number Publication date
MY162461A (en) 2017-06-15
US9029370B2 (en) 2015-05-12
PE20140968A1 (es) 2014-08-06
BR112013030698B1 (pt) 2022-05-31
EA022376B1 (ru) 2015-12-30
CN103596937B (zh) 2016-06-29
KR20140028102A (ko) 2014-03-07
EP2718271A1 (en) 2014-04-16
HK1192562A1 (zh) 2014-08-22
IL229335A0 (en) 2014-01-30
MX354410B (es) 2018-03-05
TW201307308A (zh) 2013-02-16
ES2546529T3 (es) 2015-09-24
AU2012266462A1 (en) 2013-10-31
CY1116769T1 (el) 2017-03-15
SI2718271T1 (sl) 2015-11-30
PT2718271E (pt) 2015-10-29
AU2012266462B2 (en) 2016-09-22
DK2718271T3 (en) 2015-08-24
CL2013003485A1 (es) 2014-09-12
ZA201308401B (en) 2014-08-27
HRP20151201T1 (hr) 2015-12-04
PL2718271T3 (pl) 2016-01-29
JP5788087B2 (ja) 2015-09-30
UA110388C2 (en) 2015-12-25
TWI445701B (zh) 2014-07-21
US20120316165A1 (en) 2012-12-13
AR086880A1 (es) 2014-01-29
CA2834675C (en) 2019-09-03
CA2834675A1 (en) 2012-12-13
CN103596937A (zh) 2014-02-19
SG194840A1 (en) 2013-12-30
NZ616820A (en) 2015-11-27
MA35194B1 (fr) 2014-06-02
EA201391815A1 (ru) 2014-04-30
WO2012168265A1 (en) 2012-12-13
KR101574906B1 (ko) 2015-12-04
MX2013014371A (es) 2014-01-31
IL229335A (en) 2016-11-30
EP2718271B1 (en) 2015-08-12
ECSP13013073A (es) 2014-01-31
JP2014516067A (ja) 2014-07-07
BR112013030698A2 (pt) 2016-12-06
RS54415B1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
BR302012002270S1 (pt) Configuracao aplicada em motoneta
DK2769050T3 (da) Propsensor
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
CO6811866A2 (es) Derivados de benzamida sustituida
DE102011100082A8 (de) Traygreifvorrichtung
CO6960557A2 (es) Derivados de 2-yodo-imidazol
DK3141251T3 (da) Koloskopi - forberedelse
DE112011104936A5 (de) Stanzstauchniet
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
CO6852074A2 (es) Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
DE102011117169A8 (de) Absetzplattenanordnung
DE112011105396A5 (de) Nachverfestigungsverfahren
BRDI7106825S (pt) Configuração aplicada em sandália
BRDI7106308S (pt) Configuração aplicada em sandália
BRDI7104679S (pt) Configuração aplicada em sandália

Legal Events

Date Code Title Description
FG Application granted